Delve Bio
PrivateLast Round
Series A
Jun 20, 2023
Total Funding Raised
$35M
Company Overview
Delve Bio is a biotechnology company that provides a metagenomic next-generation sequencing (mNGS) platform for the unbiased detection of neuro-infectious pathogens in cerebrospinal fluid.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Healthcare Analytics
Business Model
B2B
Customer Profile
Usage-Based SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Delve Bio Comparables
Compare Delve Bio with similar companies based on industry and business-model similarity.
Delve Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 20, 2023 |
Delve Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| S32 | Series A |
| GV | Series A |
| Perceptive Advisors | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 23, 2026
Monthly visitors grew 83% MoM, reaching 7.2K.
- Jan 1, 2024
Flagship platform Delve Detect to launch in 2024.
Delve Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Delve Bio's valuation, stock price, and market status.